Market Risers: AstraZeneca, Autins Group, Capital Ltd, Carnival

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

The trading price for AstraZeneca company symbol: LON:AZN has stepped up 4.44% or 380 points in today’s trading session so far. Market buyers have so far held a positive outlook during the trading session. The periods high has reached 8973 while the low for the session was 8540. The amount of shares exchanged has so far reached 1,050,711 with the daily average number around 2,199,043. The 52 week high price for the shares is 9335 about 786 points in difference on the previous days close and a 52 week low being 5871 is a variance of 2678 points. AstraZeneca now has a 20 SMA at 8586.73 with a 50 day MA at 8718.7. Market capitalisation for the company is £117,159.56m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Wednesday, July 15, 2020 at 1:51:00 PM GMT with the stock price trading at 8929 GBX.

The trading price for Autins Group ticker lookup code: LON:AUTG has climbed 4.71% or 0.8 points during today’s session so far. Buyers are a positive bunch during the trading session. The periods high has already touched 17.8 dropping as low as 17. The total volume traded so far comes to 12,384 with the average number of shares traded daily being 15,534. The 52 week high for the share price is 29.49 which is 12.49 points in difference to the previous days close of business and a 52 week low sitting at 7 is a variance of 10 points. Autins Group now has a 20 moving average of 16.31 and now its 50 day simple moving average now of 15.51. The market cap now stands at £7.05m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Autins Group being recorded at Wednesday, July 15, 2020 at 12:04:06 PM GMT with the stock price trading at 17.8 GBX.

The share price for Capital Ltd with ticker code: LON:CAPD has stepped up 6.4% or 4 points in today’s trading session so far. Buyers are a positive bunch during this period. The periods high has reached 67.7 and a low of 62.1. Volume total for shares traded at this point reached 271,799 whilst the daily average number of shares exchanged is just 106,967. The 52 week high for the share price is 75 amounting to 12.5 points in difference to the previous days close of business and a 52 week low sitting at 26 which is a difference of 36.5 points. Capital Ltd has a 20 SMA of 63.83 and also a 50 day SMA of 63.41. The current market cap is £91.09m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Capital Ltd being recorded at Wednesday, July 15, 2020 at 12:39:29 PM GMT with the stock price trading at 66.5 GBX.

Shares of Carnival ticker code: LON:CCL has moved up 8.44% or 80.01 points in today’s trading session so far. Buyers have stayed positive throughout the trading session. The periods high has already touched 1033 and a low of 964.72. The total volume traded so far comes to 1,453,550 whilst the daily average number of shares exchanged is just 3,708,769. A 52 week high for the stock is 3864 which comes in at 2916.4 points in difference to the previous days close of business and a 52 week low sitting at 581 a difference of some 366.6 points. Carnival has a 20 SMA of 1096.47 and now a 50 day moving average now of 1148.85. This puts the market cap at £9,442.22m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Carnival being recorded at Wednesday, July 15, 2020 at 1:50:34 PM GMT with the stock price trading at 1027.61 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.

Search

Search